鉴于肝脏的独特特征，有必要将免疫疗法与其他疗法相结合，以提高其对晚期癌症肝转移（LM）患者的疗效。高强度聚焦超声（HIFU）消融现已广泛应用于临床实践，可以增强免疫益处。该研究旨在前瞻性评估HIFU消融联合全身免疫治疗对肝转移患者的安全性和临床可行性。该研究入组了14例接受超声引导HIFU消融联合免疫检查点抑制剂（ICIs）如绵阳市中心医院抗程序性细胞死亡蛋白1（中国生产的抗PD-1药物）。试验期间使用不良事件通用术语标准 v5.0 (CTCAE v5.0) 作为标准对患者的不良事件 (AE) 进行随访。使用计算机断层扫描评估治疗后的肿瘤反应。14 名患者（年龄范围，35-84 岁）在 19 个转移部位接受了 HIFU 消融和全身免疫治疗。平均病变体积为 179.9 cm3（最大：733.1 cm3）。该试验的中位随访时间为 9 个月（范围：3-21）个月。该研究临床可行，患者可接受。本前瞻性研究证实HIFU联合免疫治疗治疗肝转移瘤临床可行且安全。版权所有：© 2024 Yang et al.这是一篇根据知识共享署名许可条款分发的开放获取文章，允许在任何媒体上不受限制地使用、分发和复制，前提是注明原始作者和来源。

Given the unique features of the liver, it is necessary to combine immunotherapy with other therapies to improve its efficacy in patients of advanced cancer with liver metastases (LM). High-intensity focused ultrasound (HIFU) ablation is now widely used in clinical practice and can enhanced immune benefits. The study is intended to prospectively evaluate the safety and clinical feasibility of HIFU ablation in combination with systemic immunotherapy for patients with liver metastases.The study enrolled 14 patients with LM who received ultrasound-guided HIFU ablation combined with immune checkpoint inhibitors (ICIs) such as anti-programmed cell death protein 1 (anti-PD-1 agents manufactured in China) at Mianyang Central Hospital. Patients were followed up for adverse events (AEs) during the trial, using the CommonTerminology Criteria for Adverse Events v5.0(CTCAE v5.0) as the standard. Tumour response after treatment was assessed using computerized tomography.The 14 patients (age range, 35-84 years) underwent HIFU ablation at 19 metastatic sites and systemic immunotherapy. The mean lesion volume was 179.9 cm3 (maximum: 733.1 cm3). Median follow-up for this trial was 9 months (range: 3-21) months. The study is clinically feasible and acceptable to patients.This prospective study confirmed that HIFU combined with immunotherapy is clinically feasible and safe for treating liver metastases.Copyright: © 2024 Yang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.